Agonistic Effects of MIF (MSH-Release Inhibiting Factor) in Levodopa-Treated Parkinsonian Patients
The use of Pro-Leu-Gly-NH2 (PLG) synthezised by NAIR et al (9) and considered as MSH-release inhibiting factor (MIF-I) in the treatment of parkinsonism is based on clinical and experimental findings. It could be shown that the application of MSH leads to an aggravation of the parkinsonian symptomatology. In animal studies it was shown that PLG (MIF-I) is able to potentiate the effects of levodopa and to antagonize the effects of reserpine and oxotremorine (for review see 8, 3). The positive effects of PLG (MIF-I) on the parkinsonian symptomatology, first shown by KASTIN and BARBEAU (2) using doses of 20-40 mg , soon were confirmed by CHASE et al (4) and FISCHER et al (6) who, in addition, could demonstrate mood elevating properties of PLG (MIF-I). This latter finding was confirmed also with larger doses of PLG in parkinsonian patients (7) and patients with endo-geneous depression (5). In the present study an analysis of the levodopa potentiating effect on motor performances, mood and drive was carried out.
Unable to display preview. Download preview PDF.
- 2.Barbeau A, Kastin AJ (1976) Polypeptide therapy in Parkinson’s disease — a new approach. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 483–487Google Scholar
- 3.Barbeau A, Roy M, Gonce M, Labrecque R (1979) Newer therapeutic approaches in Parkinson’s disease. In Poirier LJ, Sourkes TL, Bédard PJ (eds), Adv Neurol Vol 24, The extrapyramidal system and its disorders. Raven Press, New York, p 433–450Google Scholar
- 7.Gerstenbrand F, Binder H, Grünberger J, Kozmac C, Pusch St, Reisner Th (1976) Infusion therapy with MIF (melanocyte inhibiting factor) in Parkinson’s disease. In: Birmayer W, Hornykiewicz O, (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 456–461Google Scholar
- 8.Gonce M, Barbeau A (1978) Essais physiologiques avec le M. I. F.-I. dans la maladie de Parkinson. Rev Neurol (Paris) 134: 141–150Google Scholar
- 10.Schneider E, Fischer P-A, Jacobi P, Reeh W (1978) Der Einfluß von MIF (Melanozyten inhibierender Faktor) auf Psychomotorik und Stimmungsverhalten von Parkinsonkranken. Arzneim Forsch (Drug Res) 28: 1296–1297Google Scholar